Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Otezla (apremilast by Year
Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Rest of World (ROW) product sales ($M) ($M)
Amgen Otezla (apremilast: $426M in FY2025, down 0.2% from a year earlier.
Latest, FY2025
426
Period ended Dec 31, 2025
Change on a year earlier
-0.2%
427 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Rest of World (ROW) product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 426 | -0.2% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 427 | +3.9% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 411 | +2.2% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 402 | -9.7% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 445 | +9.9% | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 405 | +938.5% | Form 10-K (filed 2023-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 39 | – | Form 10-K (filed 2022-02-16) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-09) ↗ |
Cite this data
StockData. (2026). Amgen Otezla (apremilast ($M), annual FY2018–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-otezla-row
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.